Acalabrutinib + Rituximab + Chlorambucil
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Untreated Chronic Lymphocytic Leukemia
Conditions
Untreated Chronic Lymphocytic Leukemia
Trial Timeline
Jan 20, 2020 → Jan 1, 2027
NCT ID
NCT04075292About Acalabrutinib + Rituximab + Chlorambucil
Acalabrutinib + Rituximab + Chlorambucil is a phase 3 stage product being developed by AstraZeneca for Untreated Chronic Lymphocytic Leukemia. The current trial status is active. This product is registered under clinical trial identifier NCT04075292. Target conditions include Untreated Chronic Lymphocytic Leukemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04075292 | Phase 3 | Active |
Competing Products
15 competing products in Untreated Chronic Lymphocytic Leukemia